Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

Scholar Rock's apitegromab, when combined with tirzepatide (the active ingredient in Eli Lilly's Mounjaro and Zepbound), significantly reduced lean mass loss during weight loss, decreasing it from 30% to 14.6%; patients on the combination therapy lost 85% fat and only 15% lean mass. The Phase 2 EMBRAZE trial data showed apitegromab preserved an additional 4.2 pounds of lean mass compared to tirzepatide alone, potentially offering a 'higher quality' of weight loss, though total weight loss was slightly lower in the combination group; SRRK shares jumped 18% following the announcement.

Analysis

Scholar Rock's Phase 2 EMBRAZE trial demonstrated that apitegromab, when combined with tirzepatide, significantly mitigated lean mass loss associated with the GLP-1 agonist; specifically, lean mass loss was reduced from 30.2% of total weight loss with tirzepatide alone to 14.6% with the combination therapy. This represents a preservation of an additional 4.2 pounds (1.9 kilograms) or 54.9% (p=0.001) of lean mass compared to tirzepatide alone, leading to what the company terms "higher-quality weight loss," characterized by an 85% fat loss and 15% lean mass loss, compared to a 70%/30% split for the tirzepatide-placebo group. While total weight loss was marginally lower in the apitegromab-tirzepatide arm (12.3%) versus the tirzepatide-placebo arm (13.4%), the combination was generally well tolerated. This positive data, which prompted an 18% increase in SRRK's stock price to $36.77, positions apitegromab as a potentially valuable adjunct to widely used GLP-1 treatments like Eli Lilly's Mounjaro and Zepbound, especially considering competitor Regeneron reported approximately 35% lean mass loss with semaglutide alone and Eli Lilly's own interest in muscle health via its Juvena collaboration.

Key Decisions for Investors

• Consider Scholar Rock's enhanced market position due to apitegromab's potential to improve the quality of weight loss with popular GLP-1 therapies, closely tracking future clinical milestones and regulatory pathways.
• Evaluate the trade-off between significantly improved body composition (higher lean mass retention) and the marginally lower total weight loss observed with the combination therapy, as this could influence patient and physician preferences.
• Monitor the competitive landscape for muscle preservation in obesity, particularly advancements from Regeneron and Eli Lilly, to assess the sustained differentiation and market opportunity for SRRK's apitegromab.